e-learning
resources
Milan 2017
Wednesday, 13.09.2017
Idiopathic pulmonary fibrosis: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience.
A. Tzouvelekis (Athens, Greece)
Source:
International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Session:
Idiopathic pulmonary fibrosis: from the bench to the bedside
Session type:
Poster Discussion
Number:
4886
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Tzouvelekis (Athens, Greece). Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience.. 4886
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Tolerability and efficacy of Pirfenidone and Nintedanib for patients with IPF in real world clinical practice
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre.
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Real-life experience with pirfenidone in idiopathic pulmonary fibrosis (IPF) in a single centre in Italy. A retrospective study.
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Efficacy and safety of nintedanib in the elderly patient with IPF
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Budesonide/formoterol improves the wellbeing of patients with COPD: results from a real-life setting
Source: Eur Respir J 2005; 26: Suppl. 49, 289s
Year: 2005
Physician assessment of asthma control in patients receiving omalizumab in a real-world setting
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Characteristics of patients receiving mepolizumab in real-world practice –REALITI-A study
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018
Efficacy and safety of Mepolizumab in a real world severe asthma cohort.
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Flunisolide HFA demonstrates long-term safety vs two comparator drugs in the paediatric setting
Source: Eur Respir J 2001; 18: Suppl. 33, 289s
Year: 2001
Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Safety and feasibility of tight glycaemic control for COPD patients with exacerbations on the acute medical unit. Results of a phase IIa clinical trial
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2015; 24: 58-64
Year: 2015
Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis.
Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis
Year: 2019
A real life multicenter national study on the use of nintedanib in moderate to severe IPF patients
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 314s
Year: 2006
Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept